drugset
Drugs / Ritalin LA
last change Aug 2012 re-read 3 minutes ago

Ritalin LA

also known as Methylphenidate Hydrochloride · MPH
Developed for
attention deficit-hyperactivity disorder
Investigated by
Novartis Pharmaceuticals

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) RITALIN LA — 2002-06-05 fda.gov ↗

Trials 1

today
US approved 2002
NCT01259492 · Ph 3
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01259492 Nov 2010 → Aug 2012 attention deficit-hyperactivity disorder Novartis Pharmaceuticals Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Ritalin LA ClinicalTrials.gov intervention name — accepted as the source's own label NCT01259492 ↗
Known as Methylphenidate Hydrochloride “Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.” NCT01259492 ↗
Known as MPH “Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.” NCT01259492 ↗
Route Oral “taken orally once daily” NCT01259492 ↗